Finanzas de Varex Imaging Corp (VREX)VREXVarex Imaging Corp

Varex Imaging Corporation (VREX) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Medical, accounting for 63.7% of total sales, equivalent to $134.00M. Another important revenue stream is Industrial. Understanding this composition is critical for investors evaluating how VREX navigates market cycles within the Advanced Medical Equipment & Technology industry.

Evaluating the bottom line, Varex Imaging Corporation maintains a gross margin of 36.44%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 10.83%, while the net margin is 7.55%. These profitability ratios, combined with a Return on Equity (ROE) of 4.64%, provide a clear picture of how effectively VREX converts its operational activities into shareholder value.

In the context of the broader market, VREX competes directly with industry leaders such as INMD and MLAB. With a market capitalization of $781.33M, it holds a significant position in the sector. When comparing efficiency, VREX's gross margin of 36.44% stands against INMD's 74.82% and MLAB's 64.87%. Such benchmarking helps identify whether Varex Imaging Corporation is trading at a premium or discount relative to its financial performance.

Varex has shown mixed financial performance, with a gross margin of 36.44% in Q3 2026, indicating some profitability, but also a volatile earnings history with net income fluctuations, including a loss of $8.1 million in Q2 2026.